drugset
Drugs / KPL-387
last change Mar 2026 re-read 3 minutes ago

KPL-387

Developed for
pericarditis · idiopathic recurrent pericarditis
Investigated by
Kiniksa Pharmaceuticals International, plc · Kiniksa Pharmaceuticals, Ltd.

Trials 2

today NCT07288216 · Ph 2 NCT07010159 · Ph 2/3
202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT07288216 Mar 2026 → Dec 2027 expected idiopathic recurrent pericarditis, pericarditis Kiniksa Pharmaceuticals International, plc Recruiting No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT07010159 Jul 2025 → Dec 2027 expected pericarditis Kiniksa Pharmaceuticals International, plc Recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 2

DateIssuerRelease
2025-10-17 Kiniksa Pharmaceuticals International, plc Regulatory Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis kiniksa.com ↗
We are pleased to announce that yesterday the FDA granted Orphan Drug Designation to KPL-387 for the treatment of pericarditis,
2025-02-25 Kiniksa Pharmaceuticals International, plc Results Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy kiniksa.com ↗
KPL-387 Phase 1 single ascending dose data support potential monthly dosing

All press releases naming this drug 3 releases

DateIssuerRelease

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as KPL-387 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07288216 ↗
1

NCT07010159 ↗
Route Subcutaneous “administered by subcutaneous injection” NCT07010159 ↗